Hindman Andrew A.'s Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed Nov 22, 2022
- Accession no.
- 0001415889-22-011671
- Filed
- Nov 22, 2022
- Trade date
- Nov 18-20, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $716.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hindman Andrew A.CIK 0001607965 | Officer (SVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2022 | Ordinary Shares | SSaleDisposed | −65,000 | $11.02F1 | −$716,300 | 409,771 | Direct | |
| Nov 20, 2022 | Ordinary Shares | FTax withholdingDisposed | −25,057 | $10.85 | −$271,868.45 | 384,714 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.